sorafenib has been researched along with gold in 9 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (gold) | Trials (gold) | Recent Studies (post-2010) (gold) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 47,670 | 302 | 31,345 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Callaghan, C; Dash, S; Lee, BR; Liu, J; Maddox, M; Mandava, SH; Peralta, D; Tarr, MA | 1 |
| Bardia, A; Chandrakala, L; Dhayal, M; Habeeb, MA; Khan, AA; Raju, N; Sastry, BVS; Sharmila, P; Sravani, G; Vishwakarma, SK | 1 |
| Chen, X; Li, J; Xu, FJ; Yang, M; Zhang, Q; Zhao, N | 1 |
| Cui, Z; Li, Q; Li, Y; Liu, L; Liu, X; Wang, J; Wang, L; Zhang, Y | 1 |
| Ebrahim, HM; El-Rouby, MN; Ezz, MK; Morsy, ME; Said, MM | 1 |
| Barnoin, G; Bijani, C; Cuvillier, O; Fernandez Alvarez, A; Fortin, PY; Gornitzka, H; Hemmert, C; Maddelein, ML; Qin, X; Wang, X; Zhang, C | 1 |
| Dave, V; Gupta, C; Sharma, R; Sur, S | 1 |
| Cai, M; Huang, W; Xing, Y; Zhu, L; Zhuo, J | 1 |
| Darwish, W; El-Nagdy, M; Shafaa, M; Sukkar, F | 1 |
9 other study(ies) available for sorafenib and gold
| Article | Year |
|---|---|
Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Coumarins; Drug Compounding; Gold; Humans; Kidney Neoplasms; Lasers; Nanotubes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Serum Albumin; Solubility; Sorafenib | 2016 |
Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Survival; Drug Resistance, Neoplasm; Gold; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Male; Metal Nanoparticles; Microscopy, Electron, Transmission; Nanoconjugates; Particle Size; Rats, Wistar; Sorafenib | 2017 |
Rattle-Structured Rough Nanocapsules with in-Situ-Formed Gold Nanorod Cores for Complementary Gene/Chemo/Photothermal Therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Combined Modality Therapy; DNA; Drug Delivery Systems; Drug Screening Assays, Antitumor; Genetic Therapy; Gold; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Structure; Nanocapsules; Nanotubes; Particle Size; Phototherapy; Plasmids; Porosity; Silicon Dioxide; Sorafenib; Surface Properties | 2018 |
Combined chemo/photothermal therapy based on mesoporous silica-Au core-shell nanoparticles for hepatocellular carcinoma treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Drug Carriers; Drug Compounding; Drug Liberation; Gold; Humans; Hyperthermia, Induced; Lasers; Liver Neoplasms; Low-Level Light Therapy; Metal Nanoparticles; Porosity; Silicon Dioxide; Sorafenib | 2019 |
The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gold; Hep G2 Cells; Humans; Liver Neoplasms; Metal Nanoparticles; Sorafenib | 2019 |
An Artemisinin-Derivative-(NHC)Gold(I) Hybrid with Enhanced Cytotoxicity through Inhibition of NRF2 Transcriptional Activity.
Topics: Antineoplastic Agents; Artemisinins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gold; Hep G2 Cells; Humans; NF-E2-Related Factor 2; Sorafenib | 2020 |
Folic acid modified gold nanoparticle for targeted delivery of Sorafenib tosylate towards the treatment of diabetic retinopathy.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Delivery Systems; Folic Acid; Gold; Humans; Metal Nanoparticles; Sorafenib | 2020 |
Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2.
Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Movement; Cell Proliferation; Drug Carriers; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gold; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; MCF-7 Cells; Melanoma, Experimental; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Zonula Occludens-1 Protein | 2021 |
Polymeric Nanocarriers for Effective Synergistic Action of Sorafenib Tosylate and Gold-sensitized Gamma Radiation Against HepG2 Cells.
Topics: Antineoplastic Agents; Drug Carriers; Gamma Rays; Gold; Hep G2 Cells; Humans; Metal Nanoparticles; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Sorafenib | 2021 |